阿桑德西安:一种口服的小分子XIa因子抑制剂,用于治疗血栓性疾病
Nicasia D'Allesandro1, Brandon Cave1, Augustus Hough1
1West Palm Beach Veterans Affairs Medical Center, 7305 N Military Trail, West Palm Beach, FL 33410, USA.
Future cardiology
|October 13, 2023
概括
阿桑德西安是一种新型XIa因子抑制剂,显示出作为一种更安全的口服抗凝剂的前景. 目前正在进行的研究评估了它在预防中风和治疗血栓形成方面的有效性和安全性,并可能为当前疗法提供替代方案.
科学领域:
- 药理学 药理学是指药理学的学科.
- 血液学 血液学 血液学
- 心血管医学 心血管医学
背景情况:
- 口服抗凝剂如华法林和直接口服抗凝剂是血栓形成的标准,但会带来出血风险.
- 抑制XIa因子为选择性抗凝剂提供了一个潜在的机制,可以减少出血并发症.
研究的目的:
- 为了评估asundexian的安全性和有效性,一个口服XIa因子抑制剂.
- 探索asundexian作为一种潜在的比现有的抗凝剂更安全的替代品.
主要方法:
- 阿桑德西安是一种口服小分子抑制剂,向XIa因子.
- 目前正在进行临床试验,以评估其在中风预防和中风后治疗中的应用.
主要成果:
- 早期的临床数据表明,阿桑德西安是一种有希望的,比目前的抗凝药更安全的替代品.
- 正在对患有血栓形成风险增加的患者群进行进一步分析.
结论:
- 阿桑德西安的新机制可能会提供有效的抗凝剂,并提高安全性.
- 目前正在进行的研究将确定其在治疗血栓状况和预防中风方面的作用.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
726
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
726
Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
538
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
538
Antihypertensive Drugs: Vasodilators
544
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
544
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
176
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
176


